TOP > 外国特許検索 > PEPTIDE FRAGMENT FOR TREATING AUTOIMMUNE DISEASES

PEPTIDE FRAGMENT FOR TREATING AUTOIMMUNE DISEASES 新技術説明会

外国特許コード F170009151
整理番号 S2015-1886-C0
掲載日 2017年8月16日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP071224
国際公開番号 WO 2017018288
国際出願日 平成28年7月20日(2016.7.20)
国際公開日 平成29年2月2日(2017.2.2)
優先権データ
  • 特願2015-150344 (2015.7.30) JP
発明の名称 (英語) PEPTIDE FRAGMENT FOR TREATING AUTOIMMUNE DISEASES 新技術説明会
発明の概要(英語) Provided is a new means for effectively treating diseases including autoimmune diseases and the like. This peptide fragment has an amino acid sequence from position 46 to position 73, an amino acid sequence from position 160 to position 181, or an amino acid sequence from position 235 to position 261 in the amino acid sequence of carbonic anhydrase I (CAI), and includes 35 amino acid residues or less.
従来技術、競合技術の概要(英語) BACKGROUND ART
Crohn's disease and ulcerative colitis including inflammatory bowel disease (IBD) is, characterized by failure of the immune system in the intestinal tract disease. And detailed a disease not yet clear, commensal bacteria, various microbial product, a natural immunity and acquired immunity and food excessive are considered to be one of the causes of the reaction.
Immunomodulation in microenvironment is, in order to maintain local homeostasis constantly need to be finely adjusted. This adjustment can be made, site specific (for example the digestive tract environment) and, to a microbe induced by chronic exposure of the considered. Dendritic cells, plays an important role in controlling this adjustment to be responsible for the. Dendritic cells, the most potent and effective antigen presenting cell, are responsible for the induction of the initial immune response. In addition, dendritic cells are important to the formation of immune tolerance to play a role. Of immune tolerance mechanism is not fully resolved, CD4 dendritic cells+ CD25- TCD4 cells+ CD25+ Foxp3+ T controllability by to differentiate into cells, inducing an immune tolerance at the periphery T cells has been reported (see non-patent document 1) are.
Patent Document 1 is, inflammatory bowel disease in the treatment of autoimmune diseases including carbonic anhydrase I (CAI) and the pulsed tolerogenic antigen-presenting cells can be utilized have been proposed.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL UNIVERSITY CORPORATION EHIME UNIVERSITY
  • 発明者(英語)
  • HIASA, Yoichi
  • YAGI, Sen
  • ABE, Masanori
  • IKEDA, Yoshioh
  • YAMASHITA, Masakatsu
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
四国TLOは四国内20大学・高専のシーズをご紹介しております。シーズの詳細内容につきましては下記までお問い合わせください。
お問い合わせをお待ちしております。

PAGE TOP

close
close
close
close
close
close